Amicus Therapeutics Inc. (NASDAQ:FOLD) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET
Company Participants
Andrew Faughnan - Vice President, Investor Relations
Bradley Campbell - President, Chief Executive Officer
Daphne Quimi - Chief Financial Officer
Sébastien Martel - Chief Business Officer
Jeff Castelli - Chief Development Officer
Mitchell Goldman - Chief Medical Officer
Ellen Rosenberg - Chief Legal Officer
Conference Call Participants
Tazeen Ahmad - Bank of America
Anupam Rama - JPMorgan
Ritu Baral - TD Cowen
Eliana Merle - UBS
Joseph Schwartz - Leerink Partners
Dae Gon Ha - Stifel
Jeff Hung - Morgan Stanley
Kristen Kluska - Cantor Fitzgerald
Ethan Markowski - Needham & Company
Operator
Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Second Quarter 2023 Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin.
Andrew Faughnan
Thank you, Tana. Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics' second quarter 2023 financial results and corporate highlights. Leading today's call we have Bradley Campbell, President and Chief Executive Officer; Daphne Quimi, Chief Financial Officer; Sebastien Martel, Chief Business Officer and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer and Ellen Rosenberg, Chief Legal Officer.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us that any of our plans will be achieved, any or all the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements, which speak only to the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof. For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and risk factors section of our Annual Report on Form 10-K for the year ended December 31st, 2022 and the quarterly report on Form 10-Q for the quarter ended June 30, 2023 to be filed later today with the Securities and Exchange Commission.